GlassScriptPhysician profile
Leslie A Wojtowicz
NPI 1861421679
$12,386.58
in general payments reported to CMS, 2019-2025
35 companies · $2,666 in 2025
The $2,666 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $1,287 · 2023: $4,314 · 2024: $3,978 · 2025: $2,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $93.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,864.66 |
| Education | $93.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,230.34 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,851.98 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Madrigal Pharmaceuticals | $1,308.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $1,011.86 | 2023-2025 | Vemlidy, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $695.12 | 2022-2024 | Entyvio, Eohilia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $494.06 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $379.35 | 2023-2024 | Stelara, Tremfya |
| Ardelyx, INC. | $371.41 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $340.28 | 2022-2024 | Dupixent |
| Pfizer INC. | $335.35 | 2023-2024 | |
| Qol Medical, LLC | $331.08 | 2023-2024 | Sucraid, Sucraid |
| Celgene Corporation | $329.05 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $326.40 | 2023-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $273.81 | 2022-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $263.01 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $258.81 | 2024 | |
| Lilly USA, LLC | $249.61 | 2023-2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $230.84 | 2022-2024 | Rebyota, Cimzia |
| Ipsen Biopharmaceuticals, INC | $207.85 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $158.84 | 2023-2024 | Voquezna |
| Intra-Sana Laboratories | $158.25 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Scientific Affairs, LLC | $124.97 | 2022 | |
| Genzyme Corporation | $88.15 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $70.19 | 2025 | Bevespi Aerosphere |
| Daiichi Sankyo INC. | $56.09 | 2022-2024 | Injectafer |
| Novo Nordisk INC | $46.33 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $30.66 | 2022-2023 | Linzess |
| Organon LLC | $27.03 | 2024 | |
| Evoke Pharma, INC. | $26.06 | 2024 | |
| Biocon Biologics INC | $22.51 | 2024 | Hulio |
| Digestive Care, INC. | $19.68 | 2023 | Pertzye |
| Celltrion USA INC. | $17.87 | 2024 | Zymfentra |
| Orphalan INC | $17.04 | 2025 | Cuvrior |
| Mirum Pharmaceuticals, INC. | $17.01 | 2025 | Livmarli |
| Redhill Biopharma INC. | $16.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Wojtowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.